Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5586189 | 0.98 | SMN1; SMN2 (0.46) | PAK1SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL3691473 | 0.98 | SMN1; SMN2 (0.46) | PAK1SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL11821001 | 0.98 | SMN1; SMN2 (0.46) | PAK1SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL10897324 | 0.94 | USP2 (0.46) | PAK1SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL10897831 | 0.85 | HPGD (0.39) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL284354 | 0.82 | GAA (0.53) | PAK1SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL7049219 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL11334284 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL726341 | 0.75 | — | — | |
| SCHEMBL26449578 | 0.75 | KDM4E (0.57) | SMN1; SMN2ALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818648-B2 | PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; EATING DISORDERS; ALCOHOLISM; DRUG ABUSE; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-11-16 | — | — | US | disclosed |
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-6602825-B1 | Cyclization of an isocyanate with a thiourea and carbonic acid | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-05 | — | — | US | disclosed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | disclosed |
| EP-1157012-A1 | 1-ARYL-1,3,5-TRIAZINE-4-THIONE-2,6-DIONES, PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000050409-A1 | 1-ARYL-1,3,5-TRIAZINE-4-THIONE-2,6-DIONES, PRODUCTION THEREOF AND USE THEREOF AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-31 | — | — | WO | disclosed |
| EP-0920318-A4 | ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF | DU PONT PHARM CO (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0920318-A1 | ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF | Du Pont Pharmaceuticals Company (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1997035580-A1 | ARYLOXY- AND ARYLTHIOSUBSTITUTED PYRIMIDINES AND TRIAZINES AND DERIVATIVES THEREOF | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | PAK1 2552/4885SMN1; SMN2 3243/4885ALDH1A1 2751/4885 |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | PAK1 2511/4885SMN1; SMN2 3224/4885ALDH1A1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.